Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Conditions
- Metastatic Triple-Negative Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT05570253
- Locations
- đēđ¸
BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida, United States
đēđ¸Emory University (Data Collection Only), Atlanta, Georgia, United States
đēđ¸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT05546255
- Locations
- đ¨đŗ
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT05530057
- Locations
- đ°đˇ
Seoul National University Hospital, Seoul, Korea, Republic of
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
- Conditions
- Breast CancerPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05458674
- Locations
- đēđ¸
University of Colorado, Aurora, Colorado, United States
đēđ¸George Washington Medical Faculty Associates, Washington, District of Columbia, United States
đēđ¸New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
- Conditions
- TNBC - Triple-Negative Breast Cancer
- Interventions
- Drug: anti-PD-1 antibody
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05402722
- Locations
- đ¨đŗ
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 644
- Registration Number
- NCT05374512
- Locations
- đŦđ§
Research Site, Warwick, United Kingdom
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
- Conditions
- HR Positive HER2 Negative Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 87
- Registration Number
- NCT05335473
- Locations
- đ¨đŗ
Henan Cancer Hospital, Zhengzhou, China
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Biological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab Emtansine
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05206656
- Locations
- đ¨đŗ
Hunan Cancer Hospital, Changsha, Hunan, China
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 732
- Registration Number
- NCT05104866
- Locations
- đŦđ§
Research Site, Truro, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.